Key result
Ergocalciferol supplementation for 8 weeks in vitamin D deficient individuals did not improve renal plasma flow response to captopril compared to placebo (35.7 vs 35.9 ml/min per 1.73 m2).
Why the study?
Does ergocalciferol improve renin-angiotensin system activity and blood pressure in vitamin D deficient, overweight individuals without hypertension?
Population
84 vitamin D deficient (25(OH)D ≤20 ng/ml), overweight individuals without hypertension
Comparison
Ergocalciferol for 8 weeks vs Placebo for 8 weeks
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
8 weeks
Authors
Loading...
Ergocalciferol does not improve RAS activity or BP in vitamin D-deficient overweight non-hypertensives; challenges observational hypotheses.
RCT (n=84)
Double-blind
randomized
Does ergocalciferol improve renin-angiotensin system activity and blood pressure in vitamin D deficient, overweight individuals without hypertension?
Absolute Event Rate: 35.7% vs 35.9%
Correcting vitamin D deficiency with ergocalciferol for 8 weeks does not improve renin-angiotensin system activity or lower blood pressure in overweight, non-hypertensive individuals.
McMullan et al. (2016) conducted an RCT in Vitamin D deficiency in overweight individuals without hypertension (n=84). Ergocalciferol vs. Placebo was evaluated on Kidney-specific RAS activity (renal plasma flow response to captopril in high sodium balance). Ergocalciferol supplementation for 8 weeks in vitamin D deficient individuals did not improve renal plasma flow response to captopril compared to placebo (35.7 vs 35.9 ml/min per 1.73 m2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: